UT Tyler graduate earns Fulbright fellowship to study pitcher plants in Switzerland
TYLER, Texas (KETK) – Recent UT Tyler graduate Colm Conneen of Tyler has been awarded a one-year Fulbright fellowship to do postgraduate research at the University of Fribourg in Switzerland this fall.
UT Tyler celebrating evolutionary biology with Darwin Day events
Conneen, who graduated this month from UT Tyler with a bachelor's degree in biology, will go to Switzerland study the microbial microcosms in pitcher plants, a type of carnivorous plant.
'We congratulate Colm, who is a prime example of the excellent students we have in biology who go on to do amazing things,' said UT Tyler College of Arts and Sciences dean Dr. Neil Gray. 'I also want to thank Dr. Joshua Banta for being a tremendous mentor and supporter.'
Banta is a professor of biology at UT Tyler who taught Conneen and worked as his undergraduate faculty research advisor during their research on modeling the ecological niche of the Texas crayfish.
'From the moment he sought me out to work on a computational biology project, he showed a deep curiosity and determination to grow as a scientist,' Banta said. 'Our job at UT Tyler is to nurture and encourage students, and nothing makes us happier than seeing a student take full advantage of that support and then soar.'
Conneen is planning to get his doctorate degree and wants to work in ecological research and network sciences in the academic or industrial sectors. To learn more about the fellowship he received to study abroad, visit the Fulbright U.S. Student Program online.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Add-On D-Serine Shows Promise in Severe Depression
D-serine as an adjunctive treatment did not outperform placebo overall in patients with major depressive disorder (MDD), a new trial showed. However, depressive symptoms and anhedonia were significantly alleviated among patients with severe MDD, particularly among those on higher doses of standard medications. METHODOLOGY: Researchers conducted a 6-week, randomised, double-blind, placebo-controlled trial including 44 adult inpatients (mean age, 43.55 years; 45% women) diagnosed with moderate to severe MDD from Basel, Switzerland. Participants were randomly assigned in a 1:1 ratio to receive either D-serine (2 g/d) or placebo alongside standard treatment. The primary outcome was the change in clinician-rated depressive symptoms from baseline to post-intervention, measured using the 17-item Hamilton Depression Rating Scale. Secondary outcomes were self-reported depressive symptoms, anxiety, and anhedonia, measured using the Beck Depression Inventory-II, State-Trait Anxiety Inventory-1, and Snaith-Hamilton Pleasure Scale, respectively. TAKEAWAY: Both D-serine and placebo groups showed a significant reduction in symptoms across all measures, with no significant differences observed in the overall sample. In the subgroup analysis, D-serine significantly alleviated depressive symptoms in participants with severe MDD ( P = .02), with a trend towards reduction in anhedonia. = .02), with a trend towards reduction in anhedonia. In the D-serine group, clinical improvements were correlated with higher baseline depression severity and higher doses of standard medication. No serious adverse events were reported. IN PRACTICE: "DS [D-serine] may offer therapeutic benefits for patients with severe MDD, particularly when used alongside greater doses of TAU [treatment as usual] medication. These findings support the potential of DS as a synergistic adjunctive strategy to enhance the therapeutic effect of pharmacological interventions, especially in severe cases," the authors wrote. SOURCE: This study was led by Lukas Sempach, University of Basel, Basel, Switzerland. It was published online on May 26 in the Journal of Affective Disorders . LIMITATIONS: The small sample size limited the study's generalisability and reduced its power to detect small to moderate treatment effects, particularly in patients with severe depression. Additionally, the relatively low dose of D-serine used, along with its metabolism, may have limited its engagement with N-methyl-D-aspartate receptors. DISCLOSURES: This study was supported by the Gertrud Thalmann Foundation of the University Psychiatric Clinics Basel and the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung. The authors reported having no conflicts of interest.
Yahoo
a day ago
- Yahoo
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10th American Cough Conference, in Dulles, Virginia by Dr Mikhail Kalinichev, Head of Translational Science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate. 'The preclinical data obtained to date demonstrate the huge therapeutic potential of our highly selective GABAB PAM. Following in vivo proof of concept seen in a range of cough models, we are now ready to advance this candidate molecule into IND enabling studies,' said Dr Kalinichev. 'Chronic cough continues to be difficult to treat, and several different approaches being evaluated in clinical trials. Based on the data we have collected to date, we believe our GABAB PAM candidate has the potential to be an effective, once-daily treatment for patients with refractory chronic cough and other conditions.' 'This data with our novel, once daily, orally available GABAB PAM drug candidate clearly demonstrates the potential of our allosteric modulator approach to deliver a better effect than baclofen for this clinically validated drug target,' said Tim Dyer, CEO of Addex. 'Congratulations to the team and we look forward to advancing this candidate rapidly through IND enabling studies and into the clinic so we can hopefully provide better treatment options for patients.' About GABAB activation and cough: The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. About Addex Therapeutics:Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55 PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in to access your portfolio
Yahoo
2 days ago
- Yahoo
Florida Poly assistant professor receives Fulbright to continue research in Canada
Chris Kelley, an assistant professor at Florida Polytechnic University in Lakeland, has been selected by the U.S. State Department as a Fulbright Specialist. Kelley, an assistant professor of mechanical engineering, will travel to Canada in August to collaborate on academic curriculum development at the University of Windsor in Ontario, Florida Poly said in a news release. Kelley's research focuses on Parkinson's disease diagnosis and wearable care technology. The Fulbright Specialist Program provides an opportunity for U.S. academics and established professionals to engage in project-based exchanges at host institutions around the world, the release said. During Kelley's project at UWindsor, he will primarily collaborate with Jalal Ahamed, associate professor at UWindsor's Department of Mechanical, Automotive and Materials Engineering, in building mechatronics systems curriculum while incorporating biomedical aspects, the release said. Mechatronics is an interdisciplinary field that combines mechanical engineering, electronics and computer systems to design and build intelligent, automated devices and processes, the release said. 'This is a really great opportunity, and I'm excited to be a part of it,' Kelley said in the release. 'Project-based learning engages students and helps them become better problem solvers because instead of doing everything on paper, they're physically working on something and accomplishing a goal.' Kelley collaborated last year with Ahamed to develop sensors that capture changes in the gait of a person with Parkinson's disease. Ahamed was at Florida Poly as a Fulbright Canada research chair, the release said. Kelley will conduct seminars, workshops and lectures on project-based and experiential learning. Upon his return, Kelley plans to begin implementing the new methods into Florida Poly's mechatronic systems, human robotics and other courses, the release said. 'Dr. Kelley's selection as a Fulbright Specialist highlights Florida Poly's growing role on the global stage,' said Mustapha Achoubane, the senior adviser for international relationships at Florida Poly. 'We are dedicated to fostering international partnerships and academic excellence that empower our faculty and students to become leaders and innovators in science and technology worldwide.' This article originally appeared on The Ledger: Florida Poly assistant professor is named Fulbright Specialist
